Liver enzyme levels in adolescent patients treated with buprenorphine and additional psychotropic agents

Demirci, Arzu Ciftci; Güneş, Hatice; Adaletli, Hilal; Bulanik, Esra; Erdoğan, Ayten

doi:10.3109/00952990.2014.983272

Cited by 6 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…49 This favorable profile is maintained in adolescents. 50 No arrhythmia adverse event reports for patients under age 18 have been submitted to the FDA. 51…”

Section: Buprenorphine Safetymentioning

confidence: 99%

Buprenorphine in Neonatal Abstinence Syndrome

Kraft

2017

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

Infants exposed in utero to opioids will demonstrate a withdrawal syndrome known as neonatal abstinence syndrome (NAS). Buprenorphine is a long‐acting opioid with therapeutic use in medication‐assisted treatment of opioid dependency in adults and adolescents. Emerging data from clinical trials and treatment cohorts demonstrate the efficacy and safety of sublingual buprenorphine for those infants with NAS who require pharmacologic treatment. Pharmacometric modeling will assist in defining the exposure–response relationships and facilitate dose optimization.

show abstract

“…49 This favorable profile is maintained in adolescents. 50 No arrhythmia adverse event reports for patients under age 18 have been submitted to the FDA. 51…”

Section: Buprenorphine Safetymentioning

confidence: 99%

Buprenorphine in Neonatal Abstinence Syndrome

Kraft

2017

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

show abstract

“…The present study included some information from the study of our colleagues investigating the changes in liver enzyme levels associated with BUP/NAL treatment and co-medication with psychotropic agents in the same group who completed the 8-week BUP/NAL treatment at any inpatient admissions during the study period (Ciftci Demirci et al, 2015).…”

Section: Study Setting and Participantsmentioning

confidence: 99%

One-Year Follow-Up of Heroin-Dependent Adolescents Treated with Buprenorfine/Naloxone for the First Time in a Substance Treatment Unit

Mutlu

Demirci

Yalcin

et al. 2016

Journal of Substance Abuse Treatment

View full text Add to dashboard Cite

“…While we appreciate the short –term use of buprenorphine/naloxone, clinicians should continue to monitor a patients response since there have been a number of issues involving toxicity(DeVido, Connery, & Hill, 2015; Gangahar, 2015; Daniulaityte, Carlson, Brigham, Cameron, & Sheth, 2015; Ciftci et al, 2015; Edwards, McCormick-Deaton, & Hosanagar, 2014; Lavonas et al, 2013; Kim, Smiddy, Hoffman, & Nelson, 2012). One limited study suggests that buprenorphine does not affect the cingulate gyrus in early abstinent heroin addicts and as such may act as a true non-addicting pharmaceutical to prevent relapse (Mei, Zhang, & Xiao, 2010); clearly much more research is needed on this topic.…”

mentioning

confidence: 99%

Should the United States Government Repeal Restrictions on Buprenorphine/Naloxone Treatment?

Blum

Gold

Clark

et al. 2016

Substance Use & Misuse

View full text Add to dashboard Cite

Attention must be focused on needed changes to the current United States law that restricts physicians who prescribe buprenorphine for the detoxification or treatment of Opioid Use Disorder, to accepting no more than100 patients. The current system does not provide comprehensive treatment as defined by the American Society of Addiction Medicine (ASAM) criteria. Additionally, it suffers from both fragmentation and stigma and will require a significant change to comply with ASAM’s call for integrated delivery of comprehensive addiction treatment. This commentary calls for the development and implementation of “best practice,” by recommending caution in lifting the 100 patient limit until substantial achievement of this goal occurs. The authors call for an increase to 200 in the patient limit to be restricted to those physicians who are Board Certified in Addiction Medicine by the American Board of Addiction Medicine (ABAM) or in Addiction Psychiatry by the American Board of Psychiatry and Neurology (ABPN), or other responsible medical organizations. Any additional restriction lifting should follow a systemic evolution that rewards and documents competency. Such a system would involve the integration of treatment, treatment systems, and recovery with prescription medication. In addition, it should monitor emotional blunting, treatment progress and initiation of genetic addiction risk testing.

show abstract

Liver enzyme levels in adolescent patients treated with buprenorphine and additional psychotropic agents

Cited by 6 publications

References 28 publications

Buprenorphine in Neonatal Abstinence Syndrome

Buprenorphine in Neonatal Abstinence Syndrome

One-Year Follow-Up of Heroin-Dependent Adolescents Treated with Buprenorfine/Naloxone for the First Time in a Substance Treatment Unit

Should the United States Government Repeal Restrictions on Buprenorphine/Naloxone Treatment?

Contact Info

Product

Resources

About